Great Lakes Advisors LLC Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Great Lakes Advisors LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 44,048 shares of the medical device company’s stock, valued at approximately $3,426,000.

Several other institutional investors also recently made changes to their positions in DXCM. Versant Capital Management Inc bought a new position in shares of DexCom during the fourth quarter valued at approximately $25,000. Private Trust Co. NA grew its holdings in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares during the last quarter. Heck Capital Advisors LLC acquired a new position in shares of DexCom during the fourth quarter worth approximately $38,000. Finally, SBI Securities Co. Ltd. acquired a new position in shares of DexCom during the fourth quarter worth approximately $49,000. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 104,657 shares of company stock valued at $8,019,422 in the last three months. 0.30% of the stock is currently owned by company insiders.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $70.69 on Friday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The stock has a fifty day moving average of $83.99 and a 200-day moving average of $76.85. The company has a market capitalization of $27.62 billion, a PE ratio of 49.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on DXCM shares. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Citigroup boosted their price objective on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Canaccord Genuity Group boosted their price objective on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Morgan Stanley boosted their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.